ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Juvenile idiopathic arthritis"

  • Abstract Number: 1950 • ACR Convergence 2020

    Elevated Serum Gasdermin D N-terminal Implicates Macrophage Pyroptosis in Adult-onset Still’s Disease and Systemic Juvenile Idiopathic Arthritis

    Hideto Nagai1, Yohei Kirino2, Hiroto Nakano3, Yosuke Kunishita1 and Michael Ombrello4, 1Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan, 2Yokohama City University Graduate School of Medicine, Yokohama, Japan, 3NIAMS, NIH, Bethesda, 4Translational Genetics and Genomics Unit, NIAMS, NIH, Bethesda, MD

    Background/Purpose: Elevation of serum IL-18 in adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA) suggests involvement of one or more inflammasome in these…
  • Abstract Number: 0716 • ACR Convergence 2020

    Variations in Adalimumab and Etanercept Dosing in Juvenile Idiopathic Arthritis and Their Effect on Treatment Outcome: A Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Study

    Ruud Verstegen1, Peter Shrader2, Stephen Balevic3, Timothy Beukelman4, Colleen Correll5, Anne Dennos6, Thomas Phillips2 and Brian Feldman1, 1The Hospital for Sick Children, Toronto, ON, Canada, 2Duke University, Durham, 3Duke University Medical Center, Durham, 4University of Alabama at Birmingham, Birmingham, AL, 5University of Minnesota, Minneapolis, MN, 6Duke University, Durham, NC

    Background/Purpose: Different dosing strategies of adalimumab and etanercept have been used over the past decade in the treatment of juvenile idiopathic arthritis (JIA). With regards…
  • Abstract Number: 1149 • ACR Convergence 2020

    Risk Score of Macrophage Activation Syndrome (MAS) in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA)

    Simone Carbogno1, Denise Pires Marafon2, Giulia Marucci2, Emanuela Sacco2, Manuela Pardeo2, Alhanouf Alsaleem3, Sarka Fingerhutova4, Ferhat Demir5, Nastasia Cekada6, Mikhail Kostik7, Christoph Kessel8, Olga Vougiouka9, Alenka Gagro10, Jessica Tibaldi11, Francesca Minoia12, Ilaria Maccora13, Rayfel Schneider14, Pavla Dolezalova15, Betul Sozeri16, Marija Jelusic6, Antonella Insalaco2, Fabrizio De Benedetti17 and Claudia Bracaglia2, 1Pediatric Area, University of Milan, Milan, Italy, 2Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 3Division of Pediatric Rheumatology, Department of pediatrics, King Faisal specialist hospital and research center, Riyadh, Saudi Arabia, RiYADH, Saudi Arabia, 4Rheumatology Unit, Department of Paediatrics and Adolescent Medicine, Charles University in Prague, Dlouha 534, Kladno, 27201, Czech Republic, 5University of Health Sciences, Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology, Istanbul, Turkey, Istanbul, Turkey, 6University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia, Zagreb, Grad Zagreb, Croatia, 7Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, Sto arrivando!, Russia, 8Department of Pediatric Rheumatology and Immunology, University Hospital Muenster, Muenster, Germany, Muenster, Germany, 9Second Department of Paediatrics, P. & A. Kyriakou Children’s Hospital, Athens, Greece, Athens, Greece, 10Children's Hospital Zagreb, Josip Juraj Strossmayer University of Osijek, Medical Faculty Osijek, Zagreb, Croatia, Zagreb, Grad Zagreb, Croatia, 11UOC Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Italy, 12Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, 13Paediatric Rheumatology Unit, Anna Meyer Children's University Hospital, School of Human Health Science, Florence, Italy, Florence, Italy, 14University of Toronto, The Hospital for Sick Children, Toronto, Canada, 15Paediatric Rheumatology and Autoinflammatory Diseases Unit, General University Hospital, Prague, Czech Republic, Prague, Czech Republic, 16University of Health Sciences, Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology Istanbul, Turkey, Istanbul, Turkey, 17Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy

    Background/Purpose: Macrophage Activation Syndrome (MAS) is a severe, life-threatening, complication of Systemic Juvenile Idiopathic Arthritis (sJIA) with a significant mortality. A score that identify sJIA…
  • Abstract Number: 1983 • ACR Convergence 2020

    Trajectories of Disease Activity in Patients with Newly Diagnosed Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

    Natalie Shiff1, Peter Shrader2, Colleen Correll3, Anne Dennos4, Thomas Phillips2 and Timothy Beukelman5, 1Florida, Gainesville, FL, 2Duke University, Durham, 3University of Minnesota, Minneapolis, MN, 4Duke University, Durham, NC, 5University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: To describe data-derived 2-year trajectories of disease activity in patients with recently diagnosed juvenile idiopathic arthritis (JIA) as measured by the clinical Juvenile Arthritis…
  • Abstract Number: 0717 • ACR Convergence 2020

    Predictors of Clinical Remission in Children with Extended Oligoarticular Arthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis Treated with Etanercept in the CLIPPER Studies

    Jelena Vojinovic1, Vyacheslav Chasnyk1, Joke Dehoorne1, Violeta Panaviene1, Jonathan Akikusa2, Tadej Avcin1, Jeffrey Chaitow1, Bernard Lauwerys1, Jordi Antón1, Inmaculada Penades1, Berit Flato1, Alina Boteanu3, Hans-Iko Huppertz1, Juan Jaller1, Daniela Graham4, Cecilia Borlenghi5, Bonnie Vlahos6, Chuanbo Zang6 and Nicolino Ruperto2, 1Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, 2PRINTO, Istituto Giannina Gaslini, Genova, Italy, 3Hospital Universitario Ramón y Cajal, Madrid, Spain, 4Pfizer, Groton, PA, 5Pfizer, New York, NY, 6Pfizer, Collegeville, PA

    Background/Purpose: CLIPPER is an ongoing, 8-year, phase 3b, multicenter, open-label study of the safety and efficacy of etanercept in the treatment of juvenile idiopathic arthritis…
  • Abstract Number: 1150 • ACR Convergence 2020

    Traditional Laboratory Parameters and New Biomarkers in Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis

    Arianna De Matteis1, Denise Pires Marafon1, Ivan Caiello1, Manuela Pardeo1, Giulia Marucci1, Emanuela Sacco1, Giusi Prencipe1, Fabrizio De Benedetti2 and Claudia Bracaglia1, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 2Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy

    Background/Purpose: Macrophage Activation Syndrome (MAS) and secondary Hemophagocytic Lymphohistiocytosis (sHLH) are hyperinflammatory conditions caused by a cytokine storm, in which IFNγ plays a pivotal role.…
  • Abstract Number: 1984 • ACR Convergence 2020

    Causal Pathways to Health-Related Quality of Life in Children with Juvenile Idiopathic Arthritis: Results from the ReACCh-Out Cohort

    Kiem Oen1, Jiahao Tian2, Thomas Loughin2, Roberta Berard3, Mercedes Chan4, Ciaran Duffy5, Brian Feldman6, Adam Huber7, Deborah Levy8, Dax G. Rumsey9, Natalie Shiff10, Shirley Tse11, Lori Tucker4, Karen Watanabe-Duffy5 and Jaime Guzman12, 1University of Manitoba, Toronto, ON, Canada, 2Simon Fraser University, Burnaby, BC, Canada, 3London Health Sciences Centre, London, ON, Canada, 4BC Children's Hospital, Vancouver, BC, Canada, 5Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, 6The Hospital for Sick Children, Toronto, ON, Canada, 7Dalhousie University, Halifax, NS, Canada, 8Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 9University of Alberta, Edmonton, AB, Canada, 10Florida, Gainesville, FL, 11SickKids, Toronto, ON, Canada, 12University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada

    Background/Purpose: The relative roles of disease activity and disability as determinants of health-related quality of life (HRQoL) in children with JIA have been controversial; sometimes…
  • Abstract Number: 0039 • ACR Convergence 2020

    Identification of a Regulatory Pathway Governing Expression of TRAF1 via a JIA-associated Non-coding Variant

    Qiang Wang1, Marta Martínez2, Matthew Weirauch3 and Peter Nigrovic4, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, 3Cincinnati Children’s Hospital Medical Center/Univ of Cincinnati, 535 Terrace Ave, 4Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston

    Background/Purpose: Over the past decade, genome-wide association studies (GWAS) have identified TRAF1/C5 locus as a risk locus for rheumatoid diseases including RA and JIA(Plenge, Seielstad…
  • Abstract Number: 0718 • ACR Convergence 2020

    Obesity Impairs Achievement of Clinical Inactive Disease (CID) in Patients with Juvenile Idiopathic Arthritis (JIA) Treated with TNF Inhibitors

    Fabio Basta1, Denise Pires Marafon2, Angela Aquilani3, Maria Isabella Petrone4, Andrea Uva5, Hanan Jadoun6, Aurora Puccacco2, Rebecca Nicolai6, Silvia Magni Manzoni2 and Fabrizio De Benedetti7, 11 Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy 2 University Center of Autoimmunity, Johannes Gutenberg-University, Mainz, Germany 3 Acura Rheumatology Center Rhineland Palatinate, Bad Kreuznach, Germany, Mainz, Rheinland-Pfalz, Germany, 2Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 3Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Lazio, Italy, 4Dipartimento Pediatrico Universitario Ospedaliero, Tor Vergata University, Roma, Italy, 5Dipartimento Materno-Infantile e Scienze Urologiche, La Sapienza University, Rome, Italy, 6Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Lazio, Italy, 7Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy

    Background/Purpose: to assess prevalence and disease features associated with obesity in juvenile idiopathic arthritis (JIA) and to evaluate the impact of obesity on the achievement…
  • Abstract Number: 1152 • ACR Convergence 2020

    IL-18: A Biomarker That Reflects Disease Activity, Could It Be the Next Disease Activity Measure in Systemic Juvenile Idiopathic Arthritis?

    Shima Yasin1, Thuy Do2, Sanjeev Dhakal2, Elizabeth Baker2, Alexei Grom3 and Grant Schulert4, 1Cincinnati Children's Hospital Medical Center, Liberty twp, OH, 2Cincinnati Children's Hospital Medical Center, Cincinnati, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a childhood arthritis with prominent innate immune activity. Disease presentation and flares could largely mimic infections with fever…
  • Abstract Number: 1985 • ACR Convergence 2020

    Validity and Reliability of Four Parent/Patient Reported Outcome Measures for Juvenile Idiopathic Arthritis

    Chiara Trincianti1, E. H. Pieter Van Dijkhuizen2, Serena Calandra3, Helga Sanner4, Tamas Constantin5, Troels Herlin6, Marco Cattalini7, Flavio Sztajnbok8, Despoina Maritsi9, Nicolino Ruperto10, Angelo Ravelli11 and Alessandro Consolaro11, 1Istituto Giannina Gaslini, Genova, Liguria, Italy, 2Wilhelmina Children’s Hospital, Utrecht, Netherlands, 3IRCCS Istituto Giannina Gaslini, Genoa, Liguria, Italy, 4Oslo University Hospital, Oslo, Norway, 5Semmelweis University, Budapest, Hungary, 6Aarhus University Hospital, Aarhus, Denmark, 7Università di Brescia, Brescia, Italy, 8Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 9National and Kapodistrian University of Athens, Athens, Greece, 10Istituto Giannina Gaslini, Genova, Italy, 11Università degli Studi di Genova, Genoa, Italy

    Background/Purpose: In the last years, the interest in the assessment of parent- and child-reported outcomes (PCROs) in paediatric rheumatic diseases is gaining increasing importance. These…
  • Abstract Number: 0084 • ACR Convergence 2020

    Clinical Characteristics of Patients with Rheumatism of Juvenile Onset and Adult Onset in the BIOBADAGUAY Cohort

    Natalia Cabrera1, Vannia Valinotti2, Gabriela Avila-Pedretti1, Sonia Cabrera2, Patricia Melgarejo3, Zoilo Morel4, Lourdes Roman2, Pedro Babak4, Rodrigo Acosta2, Romina Glitz4, Darwin Cordovilla5, Roger Rolon4, Magali Zanotti-Cavazzoni1, Marco Antonio Franco Britos6, Marcos Vazquez2, Pedro Delgadillo4, Isabel Acosta2, María del Carmen Martinez4, Gabriel Elizaur4, María Teresa Romero4, Ernesto Paredes4, Paloma de Abreu1 and Leticia Segovia7, 1Sociedad Paraguaya de Reumatología, Asunción, Paraguay, 2Hospital de Clínicas, Asunción, Paraguay, 3Hospital IPS, Villa Rica, Paraguay, 4Hospital Central del Instituto de Previsión Social, Asunción, Paraguay, 5Instituto Nacional de Reumatología, Montevideo, Uruguay, 6Instituto de Previsi�n Social, Asunci�n, Central, Paraguay, 7Hospital del IPS, Asunción, Paraguay

    Background/Purpose: The Paraguayan-Uruguayan cohort of patients with rheumatic inflammatory diseases (BIOBADAGUAY), collect clinical and epidemiological information on adults and children patients receiving biological therapies (BT).…
  • Abstract Number: 0720 • ACR Convergence 2020

    Long Term Efficacy and Safety of Triamcinolone Hexacetonide versus Triamcinolone Acetonide Intraarticular Injection for Juvenile Idiopathic Arthritis

    Shiri Rubin1, Orly Ohana1, Ori Goldberg2, Yulia Gendler1, Zohar Habot-Wilner3, Rotem Tal4, Yoel Levinski5, Liora Harel6 and Gil Amarilyo7, 1Schneider Children's Medical Center of Israel, Petach Tikva, Israel, 2Schneider Children's Medical Center of Israel, Tel Aviv University, Tel Aviv, Israel, Petach Tikva, Israel, 3Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel, 41Schneider Children's Medical Center of Israel, Petach Tikva, Israel, 5Schneider Children's Medical Center of Israel,3Tel Aviv University, Tel Aviv, Israel, Petach Tikva, Israel, 6Scheider Children's Medical Center of Israel, Tel Aviv University, Tel Aviv, Israel, Petach Tikva, Israel, 7Schneider Children's Medical Center of Israel, Tel Aviv University, Tel Aviv, Israel,, Petach Tikva, Israel

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood. Intra-articular corticosteroids joint injection (IAJI) with Triamcinolone hexacetonide (TH) or triamcinolone acetonide…
  • Abstract Number: 1153 • ACR Convergence 2020

    Trends in Timing of Biologic Use for Treatment of Systemic Juvenile Idiopathic Arthritis in the CARRA Registry

    Ginger Janow1, Timothy Beukelman2, Yukiko Kimura3, Rayfel Schneider4, Shalini Mohan5, Gail Rodich6 and Mary Beth Son7, 1Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health, Hackensack, NJ, 2University of Alabama at Birmingham, Birmingham, AL, 3Hackensack Meridian School of Medicine, Hackensack, NJ, 4University of Toronto, The Hospital for Sick Children, Toronto, Canada, 5Genentech, Inc., South San Francisco, CA, 6Genentech, Mill Valley, CA, 7Boston Children's Hospital, Boston, MA

    Background/Purpose: The treatment of systemic juvenile idiopathic arthritis (SJIA) has changed dramatically over the past decade, associated with overall improvement in functional outcomes.  There may…
  • Abstract Number: 0164 • ACR Convergence 2020

    What’s in a Name? Patient and Family Perspectives on the Naming of Systemic Juvenile Idiopathic Arthritis

    Mariana Correia Marques1, Rashmi Sinha2, Karen Durrant3, Sivia Lapidus4, Nicole Tennermann5, Saskya Angevare6, Leah Bush7, Kari Cupp8, Jonathan Hausmann9, David Maher10, Shalla Newton10, Michael Ombrello11, Phillip Reardon8, Rebecca Trachtman12, Fatma Dedeoglu5 and Grant Schulert13, 1Boston Children`s Hospital, Department of Pediatrics, Harvard Medical School, Boston, MA, 2SJIA Foundation, Cincinnati, 3Autoinflammatory Alliance, San Francisco, CA, 4The Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Montclair, NJ, 5Boston Children's Hospital, Boston, MA, 6Autoinflammatory Alliance, Amersfoort, Netherlands, 7Systemic JIA Foundation, Cincinnati, OH, 8Systemic JIA Foundation, Cincinnati, 9Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, 10Still's Disease, the 411, National organization, 11Translational Genetics and Genomics Unit, NIAMS, NIH, Bethesda, MD, 12Icahn School of Medicine at Mount Sinai, New York, NY, 13PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

    Background/Purpose: The childhood inflammatory disorder systemic juvenile idiopathic arthritis (SJIA) has historically had several names, including Still’s disease and systemic juvenile rheumatoid arthritis. While its…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology